# Patient-Trial Match Report

*Generated: 2026-01-05 07:02:05*

## Patient Profile

- **Age**: 54
- **Sex**: Female
- **Cancer Type**: ovarian cancer
- **Biomarkers**: BRCA1 germline mutation

**Clinical Description**:
> 54-year-old female with high-grade serous ovarian cancer, germline BRCA1 pathogenic variant. Initial diagnosis Stage IIIC, underwent optimal debulking followed by carboplatin/paclitaxel x6 + niraparib maintenance. First recurrence at 18 months (platinum-sensitive), re-challenged with carboplatin/gemcitabine with PR, continued niraparib. Second recurrence now at 14 months - again platinum-sensitive interval. CA-125 rising (85 -> 340). Considering platinum rechallenge vs clinical trial. No significant residual neuropathy. Interested in novel PARP combinations or antibody-drug conjugates. Excellent performance status.

- **Location Preference**: United States, Canada

## Search Summary

- **Search terms used**: 9
- **Total trials evaluated**: 100
- **Excluded by fast filter**: 43
- **LLM scored**: 57

## ðŸŸ¢ HIGH Likelihood (23 trials)

### [NCT03564340](https://clinicaltrials.gov/study/NCT03564340)

**A Phase 1/2 Study of REGN4018 (Ubamatamab), a MUC16Ã—CD3 Bispecific Antibody, Administered Alone or in Combination With Cemiplimab in Patients With Recurrent Ovarian Cancer or Other Recurrent MUC16+ Cancers**

- **Sponsor**: Regeneron Pharmaceuticals
- **Phase**: Phase 1/Phase 2
- **Status**: Recruiting
- **Confidence**: 95%

**âœ“ Supporting Factors:**
- age: 54
- sex: female
- cancer type: ovarian cancer
- ECOG status: 0
- prior therapies: carboplatin, paclitaxel, niraparib, gemcitabine
- no brain metastases
- serum CA-125 level is currently elevated (340) which is â‰¥2 x upper limit of normal during screening
- has received at least 1 line of platinum-containing therapy (carboplatin)
- documented relapse or progression on or after the most recent line of therapy
- long-term prognosis likely exceeds 3 months

**Assessment:**
> The patient's ovarian cancer type matches the trial's target indications, and she has been previously treated with a platinum-containing therapy, fulfilling key eligibility criteria. No exclusions or uncertainties directly impact her eligibility.

---

### [NCT01441089](https://clinicaltrials.gov/study/NCT01441089)

**Collection of Blood From Therapeutic Trial Participants for Analysis of Genetic Differences in Drug Disposition and Pharmacokinetics of Probe Medications**

- **Sponsor**: National Cancer Institute (NCI)
- **Phase**: N/A
- **Status**: Recruiting
- **Confidence**: 92%

**âœ“ Supporting Factors:**
- Patient has ovarian cancer, which is one of the conditions studied in the trial.
- Patient age is 54, which meets the age requirement (>= 3 years old).
- ECOG status is 0, indicating excellent performance status.

**Assessment:**
> The patient's cancer type (ovarian cancer) matches the trial's conditions, and they meet the age and ECOG status requirements. There are no conflicting or uncertain criteria. The trial's broad eligibility allows for inclusion of previously treated patients, which aligns with the patient's treatment history.

---

### [NCT05065021](https://clinicaltrials.gov/study/NCT05065021)

**Re-VOLVE: A Phase II Clinical Trial in Women With Ovarian Cancer Progressing Post-PARP Inhibitor With Treatment Adapted to Real-time Assessment of Evolving Genomic Resistance**

- **Sponsor**: University Health Network, Toronto
- **Phase**: Phase 2
- **Status**: Recruiting
- **Confidence**: 85%

**âœ“ Supporting Factors:**
- ECOG status: 0
- Histologically confirmed high-grade serous ovarian cancer
- Patient has relapsed disease with platinum-sensitive recurrence
- Patient has measurable disease as per RECIST 1.1
- Progression on prior PARP inhibitor therapy (niraparib)
- Patient has a germline BRCA1 pathogenic variant

**? Uncertainties:**
- Adequate bone marrow, renal and hepatic function within 7 days of registration
- Left ventricular ejection fraction (LVEF) > 50%

**Assessment:**
> The patient's cancer type matches the trial criteria for high-grade serous ovarian cancer, and she has relapsed disease that is platinum-sensitive. She meets the key eligibility criteria including ECOG status and has measurable disease. However, specific organ function tests and LVEF information are not provided.

---

### [NCT06580314](https://clinicaltrials.gov/study/NCT06580314)

**A Phase III Trial of One vs. Two Years of Maintenance Olaparib, With or Without Bevacizumab, in Patients With BRCA1/2 Mutated or Homologous Recombination Deficient (HRD+) Ovarian Cancer Following Response to First Line Platinum-Based Chemotherapy**

- **Sponsor**: NRG Oncology
- **Phase**: Phase 3
- **Status**: Recruiting
- **Confidence**: 85%

**âœ“ Supporting Factors:**
- Patient has high-grade serous ovarian cancer which is included in the trial conditions studied.
- Patient has a documented BRCA1 germline mutation which meets the biomarker requirement.
- Patient is ECOG 0 which is acceptable.
- Patient has undergone cytoreductive surgery.
- Patient completed first line platinum-based therapy with required cycles.
- No brain metastases.

**? Uncertainties:**
- Lab results for creatinine clearance, absolute neutrophil count, platelets, and hemoglobin are not provided.

**Assessment:**
> The patient's cancer type matches the trial indication and they meet most eligibility criteria, although some lab results are needed for full confirmation.

---

### [NCT03419689](https://clinicaltrials.gov/study/NCT03419689)

**Biomarker Discovery Project in High Grade Serous Ovarian Cancer**

- **Sponsor**: University Health Network, Toronto
- **Phase**: Not Applicable
- **Status**: Recruiting
- **Confidence**: 85%

**âœ“ Supporting Factors:**
- Histological diagnosis of stage III high grade serous ovarian cancer
- Age is 54 (â‰¥ 18 years old)
- ECOG status is 0
- No brain metastases

**? Uncertainties:**
- Informed consent capability is assumed but not explicitly stated
- Archival tissue availability is not confirmed

**Assessment:**
> The patient's cancer type (high-grade serous ovarian cancer) aligns with the trial's focus. The patient meets the age requirement and ECOG performance status. Although the patient has a history of prior therapies, this trial does not explicitly restrict eligibility based on prior treatment lines, and the nature of the trial suggests it is focused on biological sampling rather than direct therapeutic interventions. Thus, the patient is likely eligible.

---

### [NCT04752826](https://clinicaltrials.gov/study/NCT04752826)

**Phase 1/2a Open-Label, Dose-Escalation, Multicenter, FIH, Consecutive-Cohort, Clinical Trial of BI-1808, a Monoclonal Antibody to TNFR 2 As a Single Agent and in Combination with Pembrolizumab (MK-3475-D20) in Subjects with Advanced Malignancies**

- **Sponsor**: BioInvent International AB
- **Phase**: Phase 1/Phase 2
- **Status**: Recruiting
- **Confidence**: 85%

**âœ“ Supporting Factors:**
- Histologically confirmed advanced malignancy (ovarian cancer)
- ECOG performance status of 0
- Age 54 (â‰¥18 years)
- Has a life expectancy of â‰¥12 weeks
- Prior therapy includes at least 1 systemic therapy

**? Uncertainties:**
- Adequate organ function lab values are not provided

**Assessment:**
> The patient's ovarian cancer diagnosis matches the trial's focus on advanced malignancies, specifically ovarian cancer. The patient has undergone prior systemic therapies, aligning with the trial's requirement for previously treated patients. All standard eligibility criteria appear to be met apart from the unspecified organ function values.

---

### [NCT05579366](https://clinicaltrials.gov/study/NCT05579366)

**Phase 1/2 Study of Rina-S in Patients With Locally Advanced and/or Metastatic Solid Tumors**

- **Sponsor**: Genmab
- **Phase**: Phase 1/Phase 2
- **Status**: Recruiting
- **Confidence**: 85%

**âœ“ Supporting Factors:**
- Histologically confirmed high grade serous ovarian cancer
- Received multiple prior therapies including carboplatin and paclitaxel
- BRCA1 germline mutation
- ECOG status 0
- No brain metastases

**Assessment:**
> The patient's cancer type (high grade serous ovarian cancer) matches the trial conditions. The patient has received multiple prior lines of therapy, and seems to fall within the eligibility criteria of having 1 to 3 prior therapies and being platinum-sensitive. All other criteria align well with those required by the trial, indicating a strong likelihood for eligibility.

---

### [NCT06188520](https://clinicaltrials.gov/study/NCT06188520)

**A Phase I/IIa, First-in-human, Open-label, Dose Escalation and Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of AZD8421 Alone or in Combination in Participants With Selected Advanced or Metastatic Solid Tumors**

- **Sponsor**: AstraZeneca
- **Phase**: Phase 1/Phase 2
- **Status**: Recruiting
- **Confidence**: 85%

**âœ“ Supporting Factors:**
- Female participants only
- Age 54
- ECOG status 0
- Prior treatment includes multiple lines of therapy, consistent with indicated advanced ovarian cancer
- No brain metastases
- High-grade serous ovarian cancer matches trial condition

**Assessment:**
> The patient has high-grade serous ovarian cancer, which matches the trial condition. The patient is female, aged 54, with an ECOG status of 0, no brain metastases, and has received prior therapies, suggesting advanced disease. All criteria are met without any known conflicts.

---

### [NCT06503146](https://clinicaltrials.gov/study/NCT06503146)

**18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection**

- **Sponsor**: National Cancer Institute (NCI)
- **Phase**: Phase 2
- **Status**: Recruiting
- **Confidence**: 85%

**âœ“ Supporting Factors:**
- Disease type: ovarian cancer matches trial eligibility for ovarian cancer
- ECOG status: 0 meets the requirement of ECOG performance score <= 2
- Age: 54 is >= 18 years old

**? Uncertainties:**
- Hepatic and renal function labs are not provided, making it unclear if liver transaminases and serum creatinine are within acceptable ranges

**Assessment:**
> The patient's cancer type (ovarian cancer) matches the trial's conditions studied, and she meets age and ECOG status criteria. There are uncertainties regarding her organ function labs, but overall, the eligibility is likely to be met.

---

### [NCT06395519](https://clinicaltrials.gov/study/NCT06395519)

**A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies**

- **Sponsor**: 858 Therapeutics, Inc.
- **Phase**: Phase 1/Phase 2
- **Status**: Recruiting
- **Confidence**: 85%

**âœ“ Supporting Factors:**
- Age 54
- Female sex
- Ovarian cancer diagnosis
- BRCA1 mutation
- ECOG status 0
- Prior therapies include carboplatin and niraparib
- No brain metastases

**? Uncertainties:**
- The patient has received multiple prior therapies but it is unclear if these meet the threshold of having progression on or after a systemic therapy as required by trial criteria.
- No recent organ function labs provided to confirm suitability.

**Assessment:**
> The patient's cancer type (ovarian cancer with BRCA1 mutation) matches the conditions studied in the trial. The patient is not treatment-naive, but there is no exclusion from the trial for previously treated patients. The performance status is excellent, and there are no brain metastases which meets the eligibility criteria. There are minor uncertainties regarding the confirmation of criteria surrounding prior therapies and organ function.

---

### [NCT02732860](https://clinicaltrials.gov/study/NCT02732860)

**Prospective Evaluation of Freshly Implanted Cancers in Mice to Test Drug Response in Matching Host**

- **Sponsor**: University Health Network, Toronto
- **Phase**: N/A
- **Status**: Recruiting
- **Confidence**: 85%

**âœ“ Supporting Factors:**
- Patient has histologically-confirmed advanced High Grade Serous Ovarian Cancer.
- Patient has an ECOG status of 0.
- Patient is willing and able to provide signed voluntary informed consent.

**? Uncertainties:**
- Patient's organ function is unknown.

**Assessment:**
> The patient's diagnosis of high-grade serous ovarian cancer matches the conditions studied in the trial, and her previous treatments indicate she is a candidate for this type of research. Additionally, she meets the age and ECOG status requirements. There is uncertainty around organ function, but overall she fits the eligibility criteria.

---

### [NCT03702309](https://clinicaltrials.gov/study/NCT03702309)

**Liquid Biopsy Evaluation and Repository Development at Princess Margaret**

- **Sponsor**: University Health Network, Toronto
- **Phase**: N/A
- **Status**: Recruiting
- **Confidence**: 85%

**âœ“ Supporting Factors:**
- Patient has histological confirmation of ovarian cancer
- Patient is 54 years old
- Patient has ECOG status of 0
- Patient has BRCA1 germline mutation

**Assessment:**
> The patient's cancer type (ovarian cancer) aligns with the conditions studied in the trial. The patient is previously treated but does not have a specified treatment line requirement for eligibility. The patient meets age and performance status guidelines, and there are no conflicting exclusion criteria.

---

### [NCT04314401](https://clinicaltrials.gov/study/NCT04314401)

**Cancer Moonshot Biobank Research Protocol**

- **Sponsor**: National Cancer Institute (NCI)
- **Phase**: N/A
- **Status**: Recruiting
- **Confidence**: 85%

**âœ“ Supporting Factors:**
- Cancer type is high-grade serous ovarian cancer, which is included in the trial conditions studied.
- Patient ECOG status is 0, which is acceptable for eligibility.
- Patient is 54 years old, which meets the age criteria of 13 or older.
- Patient has a BRCA1 germline mutation, meeting the specific biomarker inclusion criteria.

**Assessment:**
> The patient's cancer type matches the trial's inclusion criteria specifically for high-grade serous ovarian cancer. The patient is previously treated, but no clear exclusion based on treatment line is indicated in the trial criteria. Additionally, the patient has a relevant biomarker (BRCA1 mutation). All other general eligibility criteria are met, leading to a high likelihood of eligibility.

---

### [NCT05142033](https://clinicaltrials.gov/study/NCT05142033)

**Implementation of Comprehensive Molecular Profiling and Deep Clinical Annotation of Electronic Health Records in Participants Diagnosed With or at Risk of Developing Cancer (ASAP Study)**

- **Sponsor**: Avera McKennan Hospital & University Health Center
- **Phase**: N/A
- **Status**: Recruiting
- **Confidence**: 85%

**âœ“ Supporting Factors:**
- Patient has ovarian cancer, which is listed as a condition studied in the trial.
- Patient is 54 years old, meeting the age criterion of at least 18.
- Patient has an ECOG status of 0, indicating excellent performance status.
- Patient is undergoing a follow-up for a diagnosed cancer.

**Assessment:**
> The patient's ovarian cancer aligns with the trial's focus on gynecologic cancers, and she meets the age and performance status criteria. There are no explicit conflicts or uncertainties in the provided data.

---

### [NCT05039801](https://clinicaltrials.gov/study/NCT05039801)

**A Phase 1 Open-Label, Dose-Escalation and Dose-Expansion Study to Investigate the Safety, Pharmacokinetics, and Anti-Tumor Activity of IACS-6274 as Monotherapy and in Combination in Patients With Advanced Solid Tumors**

- **Sponsor**: M.D. Anderson Cancer Center
- **Phase**: Phase 1
- **Status**: Recruiting
- **Confidence**: 85%

**âœ“ Supporting Factors:**
- Patient has advanced ovarian cancer, specifically high-grade serous ovarian cancer, which matches the study conditions.
- ECOG status is 0, indicating excellent performance.
- Patient is 54 years old, above the age of 18 requirement.
- Prior therapies align with the eligibility criteria as the patient has undergone more than one line of therapy.
- Patient is interested in novel PARP combinations or antibody-drug conjugates, aligning with the trial's focus.
- No significant residual neuropathy.

**? Uncertainties:**
- The specific lab values confirming adequate organ function are not provided.
- Relation of the patient's germline BRCA1 mutation to eligibility criteria is not clarified in the provided information.

**Assessment:**
> The patient's diagnosis matches the trial conditions as they have high-grade serous ovarian cancer, which is included in the study's conditions for advanced ovarian cancer. Their treatment history indicates they are a previously treated patient, which fits the trial requirements. Their ECOG status is excellent, supporting eligibility. However, concrete lab values for organ function and the implications of their BRCA1 mutation remain uncertain.

---

### [NCT05787587](https://clinicaltrials.gov/study/NCT05787587)

**A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors**

- **Sponsor**: IDEAYA Biosciences
- **Phase**: Phase 1
- **Status**: Recruiting
- **Confidence**: 85%

**âœ“ Supporting Factors:**
- Patient has advanced ovarian cancer.
- Patient has a documented BRCA1 germline mutation.
- Patient has progressed on multiple prior lines of therapy.

**Assessment:**
> The patient's cancer type (ovarian cancer) matches the trial criteria. The patient has a BRCA1 mutation, which is a required biomarker for Module 1 of the trial. The patient is also previously treated, which aligns with the expected treatment line for the trial. No conflicts or uncertainties were noted in the evaluation.

---

### [NCT05989724](https://clinicaltrials.gov/study/NCT05989724)

**A First-in-Human (FIH), Open-Label, Phase Ia/Ib Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SON-DP in Participants With Relapsed/Metastatic Solid Tumors**

- **Sponsor**: Qurgen Inc.
- **Phase**: Phase 1
- **Status**: Recruiting
- **Confidence**: 85%

**âœ“ Supporting Factors:**
- Patient has high-grade serous ovarian cancer, which is included in the trial conditions studied.
- Patient is female and aged 54, which meets the age criteria of â‰¥ 18 years.
- ECOG performance status of 0, meeting the criteria for study entry.
- Patient has significant prior treatments, which aligns with being relapsed/refractory.

**? Uncertainties:**
- Adequate hematological function is unspecified.
- Adequate hepatic/renal function is unspecified.
- Acceptable coagulation function is unspecified.
- Recovery from prior treatment adverse effects is unspecified.

**Assessment:**
> The patient's cancer type matches the trial indication, and all major criteria are satisfied. The trial is appropriate for previously treated patients, which aligns with the patient's treatment history.

---

### [NCT06177171](https://clinicaltrials.gov/study/NCT06177171)

**A Phase I/Ib Study of Olaparib and ASTX727 in BRCA1/2- and HRD-mutated Tumors**

- **Sponsor**: Pamela Munster
- **Phase**: Phase 1
- **Status**: Recruiting
- **Confidence**: 85%

**âœ“ Supporting Factors:**
- Histologically confirmed advanced solid tumor type (ovarian cancer)
- Germline BRCA1 mutation
- ECOG status 0
- No brain metastases
- Prior therapies include PARP inhibitors
- Age 54 (>=18 years)

**? Uncertainties:**
- Specific organ function labs are not provided

**Assessment:**
> The patient's cancer type (ovarian cancer with a germline BRCA1 mutation) matches the trial's requirements. The patient has prior treatment but is still eligible as the trial allows for previously treated patients. The ECOG performance status is acceptable, and there are no conflicts with brain metastases or age. Although specific organ function labs are not provided, the patient meets all other major eligibility criteria.

---

### [NCT06582017](https://clinicaltrials.gov/study/NCT06582017)

**A First-in-human Phase 1a/1b Study to Evaluate Safety and Tolerability of QXL138AM in Patients With Locally Advanced Un-resectable and/or Metastatic Solid Tumors and Multiple Myeloma**

- **Sponsor**: Nammi Therapeutics Inc
- **Phase**: Phase 1
- **Status**: Recruiting
- **Confidence**: 85%

**âœ“ Supporting Factors:**
- Patient has a confirmed diagnosis of ovarian cancer, which is one of the studied conditions.
- Patient is 54 years old, which meets the age criteria.
- Patient has an ECOG status of 0, which is acceptable.
- Patient has no brain metastases, which is favorable.

**? Uncertainties:**
- Adequate organ function and bone marrow reserve (not explicitly confirmed).
- Cardiac function (left ventricular ejection fraction not provided).

**Assessment:**
> The patient's cancer type of ovarian cancer matches the conditions studied in the trial. Additionally, the patient is previously treated, which aligns with the trial's inclusion of participants who have progressed despite standard therapies. There are some uncertainties regarding organ and cardiac function, but overall, the patient meets the key eligibility criteria.

---

### [NCT03428802](https://clinicaltrials.gov/study/NCT03428802)

**A Basket Trial of Pembrolizumab in Patients With Advanced Solid Tumors and Genomic Instability**

- **Sponsor**: Rutgers, The State University of New Jersey
- **Phase**: Phase 2
- **Status**: Recruiting
- **Confidence**: 80%

**âœ“ Supporting Factors:**
- Diagnosis of high-grade serous ovarian cancer
- BRCA1 germline mutation
- ECOG status of 0

**? Uncertainties:**
- Absolute neutrophil count (ANC), Platelets, Hemoglobin, Serum creatinine, Serum total bilirubin, AST and ALT levels, Albumin levels, INR or PT, aPTT levels - specific lab values are not provided and need to be verified

**Assessment:**
> The patient's cancer type of high-grade serous ovarian cancer with a BRCA1 mutation is aligned with the trial's focus on BRCA gene mutations and recurrent ovarian carcinomas. Additionally, the patient's ECOG status of 0 meets the performance status requirement. Although laboratory values for organ function and blood counts are not provided, which introduces some uncertainties, the overall profile indicates they likely meet the eligibility criteria.

---

### [NCT05694715](https://clinicaltrials.gov/study/NCT05694715)

**Combination Therapy of Niraparib and Irinotecan in Cancers With Mutations in DNA Repair Genes**

- **Sponsor**: University of California, San Francisco
- **Phase**: Phase 1
- **Status**: Recruiting
- **Confidence**: 80%

**âœ“ Supporting Factors:**
- Patient has high-grade serous ovarian cancer, which is included in the trial's conditions studied.
- Patient has a BRCA1 germline mutation, which meets the biomarker requirement of the trial.
- Patient's ECOG status is 0, which is acceptable for the trial.
- Patient is 54 years old, which meets the age requirement.

**? Uncertainties:**
- Specific organ function test results (e.g., ANC, hemoglobin, platelets) are not provided.
- Washout period confirmation since last therapy is not provided.

**Assessment:**
> The patient's cancer type and required biomarker match the trial criteria. Patient has prior treatments, but they do not conflict with the trial's eligibility as it allows prior therapies. The ECOG status meets trial requirements, leading to a high likelihood of eligibility despite some uncertainties regarding organ function and washout.

---

### [NCT05512208](https://clinicaltrials.gov/study/NCT05512208)

**A Phase 2 Study of VS-6766 (Dual RAF/MEK Inhibitor) Plus Defactinib (FAK Inhibitor) in Recurrent Gynecological Cancers (DURAFAK)**

- **Sponsor**: University of Oklahoma
- **Phase**: Phase 2
- **Status**: Recruiting
- **Confidence**: 75%

**âœ“ Supporting Factors:**
- Patient has high-grade serous ovarian cancer, which matches the trial's conditions studied.
- Patient is a female aged 54, which satisfies the age requirement.
- ECOG status of 0 is within the allowed range (â‰¤2).
- Patient has adequate performance status.

**? Uncertainties:**
- No lab results provided for organ function parameters.
- Specific mutational status regarding RAS or BRAF needs verification, as only BRCA1 mutation is mentioned.

**Assessment:**
> The patient's cancer type matches the trial's focus on high-grade serous ovarian cancer. Although the patient has had prior therapies, the trial is designed for previously treated patients, and the data provided supports her eligibility for the study's criteria; however, confirmation of mutational status and organ function would bolster her candidacy.

---

### [NCT05005403](https://clinicaltrials.gov/study/NCT05005403)

**A Global First-in-Human Study in NSCLC, HNSCC and Solid Tumors With Azirkitug (ABBV-514) as a Single Agent and in Combination With Budigalimab or Bevacizumab**

- **Sponsor**: AbbVie
- **Phase**: Phase 1
- **Status**: Recruiting
- **Confidence**: 75%

**âœ“ Supporting Factors:**
- Patient has high-grade serous ovarian cancer, which is included in the trial's conditions studied.
- ECOG status is 0, meeting the trial's requirement of ECOG <=1.

**âœ— Potential Conflicts:**
- Patient has prior therapies that may exclude her from the criteria for High-Grade Serous Ovarian Cancer, which states 'Progressed serous epithelial ovarian, fallopian tube or primary peritoneal cancer post SOC and not eligible for surgical resection.'

**? Uncertainties:**
- Patient's hormonal status or specific laboratory values are not provided.
- Presence of measurable disease per RECIST is not confirmed as CA-125 levels alone may not suffice.

**Assessment:**
> The patient's cancer type is included in the trial study conditions, and her ECOG status meets the eligibility criteria. However, her prior treatments may conflict with the trial requirements regarding progression after standard of care. Additional information about measurable disease and specific lab values is needed for full confidence.

---

## ðŸŸ¡ MEDIUM Likelihood (3 trials)

### [NCT04657068](https://clinicaltrials.gov/study/NCT04657068)

**A Phase I/IIa, Open-label, Multi-center Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of the ATR Kinase Inhibitor ART0380 Administered Orally as Monotherapy and in Combination to Patients With Advanced or Metastatic Solid Tumors**

- **Sponsor**: Artios Pharma Ltd
- **Phase**: Phase 1/Phase 2
- **Status**: Recruiting
- **Confidence**: 65%

**âœ“ Supporting Factors:**
- Female patient with germline BRCA1 pathogenic variant
- Performance status of 0 on the ECOG scale
- Patient is from the United States

**âœ— Potential Conflicts:**
- Patient has had multiple prior therapies (carboplatin, paclitaxel, niraparib, gemcitabine), which may exceed the limits for eligibility regarding previous treatments.

**? Uncertainties:**
- Hematologic, renal, hepatic, and coagulation functions are unknown.
- Tumor tissue sample availability is not mentioned.

**Assessment:**
> The patient's diagnosis of advanced ovarian cancer aligns with the trial's conditions studied, specifically ovarian cancer. However, she has undergone multiple prior treatments, raising questions about her eligibility, especially considering the trial's focus on treatment-naive patients or those fitting specific criteria around prior therapies. Thus, several factors need verification to confirm her eligibility.

---

### [NCT05746897](https://clinicaltrials.gov/study/NCT05746897)

**A Phase 1 Study to Investigate the Safety, Tolerability, Pharmacokinetics/Pharmacodynamics, and Antitumor Activity of NM1F as Monotherapy and in Combination With Pembrolizumab in Subjects With Locally Advanced/Metastatic Solid Tumors**

- **Sponsor**: Hefei TG ImmunoPharma Co., Ltd.
- **Phase**: Phase 1
- **Status**: Recruiting
- **Confidence**: 65%

**âœ“ Supporting Factors:**
- Age: 54
- Sex: female
- Cancer type: ovarian cancer
- ECOG status: 0
- Prior therapies: treated with carboplatin, paclitaxel, niraparib, gemcitabine
- No brain metastases

**âœ— Potential Conflicts:**
- Patient has prior systemic therapies but trial requires subjects who have progressed despite all standard therapy or are intolerant of all standard therapy.

**? Uncertainties:**
- Sufficient baseline organ function and laboratory data are not provided.

**Assessment:**
> The patient's cancer type matches as the trial studies ovarian cancer. However, the patient has received multiple prior therapies, which raises concerns as the trial appears to focus on patients progressing after standard treatments. There are also uncertainties regarding organ function.

---

### [NCT06257264](https://clinicaltrials.gov/study/NCT06257264)

**A Phase 1a/1b Study of BG-68501, a Selective CDK2 Inhibitor, in Participants With Advanced Solid Tumors**

- **Sponsor**: BeiGene
- **Phase**: Phase 1
- **Status**: Recruiting
- **Confidence**: 65%

**âœ“ Supporting Factors:**
- Age: 54
- Sex: female
- Cancer type: ovarian cancer
- ECOG status: 0
- Prior therapies: carboplatin, paclitaxel, niraparib, gemcitabine
- Brain metastases: none

**âœ— Potential Conflicts:**
- Trial targets platinum refractory or resistant serous ovarian cancer; patient is classified as having high-grade serous ovarian cancer but does not specifically state being platinum refractory or resistant.

**? Uncertainties:**
- Specific organ function metrics are not provided.
- Biomarker criteria for this trial are not specified; it is unclear if BRCA1 mutation impacts eligibility.

**Assessment:**
> The patient's cancer type of high-grade serous ovarian cancer is included in the trial, but it is unclear if the patient's platinum treatment history meets the specific requirement of being refractory or resistant. There are also uncertainties regarding specific organ function metrics and the relevance of the patient's BRCA1 mutation to eligibility. Thus, while the patient likely qualifies, further details are needed.

---

## ðŸŸ  LOW Likelihood (1 trials)

### [NCT05281471](https://clinicaltrials.gov/study/NCT05281471)

**A Randomized Phase 3 Study Assessing the Efficacy and Safety of Olvi-Vec Followed by Platinum-doublet Chemotherapy and Bevacizumab Compared With Physician's Choice of Chemotherapy and Bevacizumab in Women With Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)**

- **Sponsor**: Genelux Corporation
- **Phase**: Phase 3
- **Status**: Recruiting
- **Confidence**: 29%

**âœ“ Supporting Factors:**
- Age: 54
- Sex: female
- Cancer type: high-grade serous ovarian cancer
- ECOG status: 0
- Prior therapies: carboplatin, paclitaxel, niraparib, gemcitabine

**âœ— Potential Conflicts:**
- Trial is for platinum-resistant/refractory ovarian cancer, patient has platinum-sensitive disease.

**? Uncertainties:**
- Platinum-free interval (PFI) from last dose of platinum therapy to progression is unclear.

**Assessment:**
> The patient's cancer type is high-grade serous ovarian cancer, which fits the trial's focus on high-grade serous and similar types. However, the trial explicitly assesses platinum-resistant/refractory disease, while the patient is currently described as having platinum-sensitive disease, leading to a likely exclusion based on the criteria for disease status.

---

## Excluded (72 trials)

### Excluded by Fast Filter

| NCT ID | Reason |
|--------|--------|
| [NCT04251052](https://clinicaltrials.gov/study/NCT04251052) | Patient age 54 is above maximum age 50 |
| [NCT02693535](https://clinicaltrials.gov/study/NCT02693535) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT04038502](https://clinicaltrials.gov/study/NCT04038502) | Trial requires male patients |
| [NCT04300556](https://clinicaltrials.gov/study/NCT04300556) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT05128825](https://clinicaltrials.gov/study/NCT05128825) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT05327010](https://clinicaltrials.gov/study/NCT05327010) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT05498272](https://clinicaltrials.gov/study/NCT05498272) | Trial requires male patients |
| [NCT05806515](https://clinicaltrials.gov/study/NCT05806515) | Trial requires male patients |
| [NCT05879926](https://clinicaltrials.gov/study/NCT05879926) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT05902988](https://clinicaltrials.gov/study/NCT05902988) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT00488878](https://clinicaltrials.gov/study/NCT00488878) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT00823654](https://clinicaltrials.gov/study/NCT00823654) | Patient age 54 is above maximum age 44 |
| [NCT00929006](https://clinicaltrials.gov/study/NCT00929006) | Patient age 54 is above maximum age 17 |
| [NCT01102569](https://clinicaltrials.gov/study/NCT01102569) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT01870752](https://clinicaltrials.gov/study/NCT01870752) | Patient age 54 is above maximum age 45 |
| [NCT01970696](https://clinicaltrials.gov/study/NCT01970696) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT02296307](https://clinicaltrials.gov/study/NCT02296307) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT02333604](https://clinicaltrials.gov/study/NCT02333604) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT03568630](https://clinicaltrials.gov/study/NCT03568630) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT04254133](https://clinicaltrials.gov/study/NCT04254133) | Trial requires male patients |
| ... | *and 23 more* |

### Excluded by Eligibility Assessment

| NCT ID | Sponsor | Reason |
|--------|---------|--------|
| [NCT05752448](https://clinicaltrials.gov/study/NCT05752448) | Baylor College of Me | Patient is not within 6 months of completion of initial treatment, as they have had two recurrences and are considering treatment options. |
| [NCT04787289](https://clinicaltrials.gov/study/NCT04787289) | British Columbia Can | Trial requires platinum resistant disease, patient has platinum sensitive disease |
| [NCT04918186](https://clinicaltrials.gov/study/NCT04918186) | Canadian Cancer Tria | Trial is for platinum resistant high grade serous ovarian cancer, patient has platinum-sensitive disease |
| [NCT05961124](https://clinicaltrials.gov/study/NCT05961124) | Sunnybrook Health Sc | Patient has a BRCA1 mutation, which is an exclusion criterion for this trial. |
| [NCT05998135](https://clinicaltrials.gov/study/NCT05998135) | Emory University | The patient has high-grade serous ovarian cancer, but the trial is specifically for platinum-resistant ovarian cancer. The patient is currently platinum-sensitive. |
| [NCT06315491](https://clinicaltrials.gov/study/NCT06315491) | Cybrexa Therapeutics | Patient is not platinum-resistant; currently has platinum-sensitive disease. |
| [NCT04794322](https://clinicaltrials.gov/study/NCT04794322) | Massachusetts Genera | Patient has prior treatments for ovarian cancer, which does not match the criteria for Cohort 1 (untreated) or Cohort 2 (requires risk-reducing salpingo-oophorectomy - not indicated for recurrent cases) |
| [NCT05300711](https://clinicaltrials.gov/study/NCT05300711) | University of Britis | Patient has a BRCA1 germline mutation which is an exclusion criterion for the trial. |
| [NCT05429970](https://clinicaltrials.gov/study/NCT05429970) | Memorial Sloan Kette | Patient has received multiple prior treatments (carboplatin, paclitaxel, niraparib, gemcitabine), while the trial requires treatment-naive or first-line patients. |
| [NCT06459271](https://clinicaltrials.gov/study/NCT06459271) | University Health Ne | The trial is for patients with newly diagnosed or recurrent advanced ovarian cancer but the patient has already had multiple lines of therapy. |
| [NCT06545604](https://clinicaltrials.gov/study/NCT06545604) | M.D. Anderson Cancer | Patient has completed chemotherapy (received carboplatin, paclitaxel, niraparib, gemcitabine). |
| [NCT04890613](https://clinicaltrials.gov/study/NCT04890613) | Senhwa Biosciences,  | Trial is for patients with BRCA2 or PALB2 mutations, not BRCA1. |
| [NCT05287451](https://clinicaltrials.gov/study/NCT05287451) | M.D. Anderson Cancer | Patient is 54 years old but trial criteria require age 25-40 for BRCA1 mutation carriers. |
| [NCT04633239](https://clinicaltrials.gov/study/NCT04633239) | National Cancer Inst | Patient has platinum-sensitive recurrent ovarian cancer, whereas the trial is for recurrent platinum-resistant ovarian cancer |
| [NCT04090567](https://clinicaltrials.gov/study/NCT04090567) | M.D. Anderson Cancer | Patient has ovarian cancer; trial is for breast cancer. |
| [NCT06504147](https://clinicaltrials.gov/study/NCT06504147) | Oncoinvent AS | Patient has a BRCA1 germline mutation; the trial has exclusion criteria for known somatic or germline BRCA1 or BRCA2 mutations. |
| [NCT02302742](https://clinicaltrials.gov/study/NCT02302742) | University of Kansas | Trial is for patients with Triple Negative Breast Cancer (TNBC), while the patient has high-grade serous ovarian cancer. |
| [NCT03772028](https://clinicaltrials.gov/study/NCT03772028) | The Netherlands Canc | prior treatment for the current malignancy (carboplatin, paclitaxel, niraparib, gemcitabine) |
| [NCT06083844](https://clinicaltrials.gov/study/NCT06083844) | M.D. Anderson Cancer | Patient has a known germline BRCA1 mutation which may disqualify from trial eligibility as there is a specific exclusion criterion for known deleterious germline BRCA mutations |
| [NCT06639074](https://clinicaltrials.gov/study/NCT06639074) | Mayo Clinic | Patient has a germline BRCA1 mutation, which is an exclusion criterion for this trial. |
| ... | ... | *and 9 more* |

## Search Terms Used

| Term | Source | Confidence |
|------|--------|------------|
| BRCA1 germline mutation | manual | 1.0 |
| ovarian cancer | manual | 1.0 |
| BRCA1 germline mutation ovarian cancer | manual | 1.0 |
| BRCA1 germline mutation high-grade serous ovarian cancer | llm | 0.9 |
| BRCA1 mutation ovarian cancer | llm | 0.9 |
| high-grade serous ovarian cancer | llm | 0.8 |
| Ovarian carcinoma | llm | 0.8 |
| BRCA1 pathogenic variant | llm | 0.9 |
| BRCA1 | llm | 0.9 |

## Information That Would Improve Matches

The following patient data was not provided but would help refine eligibility assessment:

- **Organ function labs** (hematology, liver, renal) - required by all interventional trials
- **Measurable disease status** (per RECIST 1.1) - required for most therapeutic trials
- **Cardiac status/QTc interval** - relevant for trials with cardiotoxicity risk
